![]() Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. JNCI Journal of the National Cancer Institute Way to Better DNA. Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R et al (2005) A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: Results after 5 years of follow-up. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP et al (2005) Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trial. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. Measuring inconsistency in meta-analyses. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Hazard Ratio Calculator-Calculate Hazard Ratio, HR Confidence Intervals & p-value. Introduction-GRADE evidence profiles and summary of findings tables. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al (2011) GRADE guidelines: 1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P et al (2008) A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the sentinella/GIVOM trial. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V et al (2010) Sentinel lymph node biopsy in breast cancer: ten-year results: of a randomized controlled study. Breast Cancer Res Treat 170(2):303–312Ĭanavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E et al (2016) Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. Roy P, Leizorovicz A, Villet R, Mercier C, Bobin JY (2018) Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Kelley MC, Hansen N, McMasters KM (2004) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Peintinger F, Reitsamer R, Stranzl H, Ralph G (2003) Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Krag DN, Weaver DL, Alex JC, Fairbank JT (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Lippincott Williams and Wilkins, pp 391–401 Giuliano AE, Kirgan DM, Guenther JM, Morton DL (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Systematic axillary axillary lymph node dissection provides no survival benefit compared with sentinel lymph node dissection for early-stage clinically node-negative breast cancer patients. No statistically significant difference was observed in any of secondary study outcomes. Locoregional recurrence was observed in 2.8% (ALND) vs. No statistically significant difference was observed in locoregional recurrence, breast cancer-related death and overall death. There were four studies included in the analysis, enrolling overall 2982 patients, of which 1494 in ALND arm and 1488 in the SLN ± ALND arm. Primary endpoints were locoregional recurrence, overall death and cancer-related death. Patients enrolled were only those with tumor size lower than 4 cm, clinically negative nodes and treated with breast-conservative surgery. SLN ± ALND in early-stage, node-negative breast cancer patients. Included studies were prospective randomized controlled trials (RCTs) comparing survival outcomes of ALND vs. ΜethodsĪ systematic review and meta-analysis adhered to PRISMA guidelines was performed. This study aimed at comparing survival outcomes between systematic axillary lymph node dissection (ALND) vs sentinel lymph node and axillary lymph node dissection only if sentinel positive (SLN ± ALND) in early-stage, clinically node-negative breast cancer patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |